Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

By Rogers S.L.   Doody R.S.   Pratt R.D.   Ieni J.R.  

European Neuropsychopharmacology, Vol. 10, Iss. 3, 2000-05 ,pp. : 195-203

Elsevier

Access to resources Recommend Favorite

Long-Term Effects of Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing Home Patients with Alzheimer’s Disease: Results of a 52-Week Open-Label Study

By Edwards Keith  

Clinical Drug Investigation, Vol. 25, Iss. 8, 2005-01 ,pp. : 507-515

Adis International

Access to resources Recommend Favorite

Long-Term Safety, Tolerability and Efficacy of Fesoterodine in Subjects with Overactive Bladder Symptoms Stratified by Age: Pooled Analysis of Two Open-Label Extension Studies

By Sand Peter K.  

Drugs & Aging, Vol. 29, Iss. 2, 2012-02 ,pp. : 119-131

Adis International

Access to resources Recommend Favorite

Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension: A Randomized, Open-Label, Parallel-Group, Multicentre, Dose-Escalation Study with an Extension Phase

By Sica Domenic  

Clinical Drug Investigation, Vol. 31, Iss. 12, 2011-12 ,pp. : 825-837

Adis International

Access to resources Recommend Favorite

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease

By Wilcock G.  

Drugs & Aging, Vol. 20, Iss. 10, 2003-01 ,pp. : 777-789

Adis International

Access to resources Recommend Favorite